As a pioneer and an undisputed global leader in new therapy development, the goal of Creative Biolabs is to provide global customers with the most affordable and top-quality mesenchymal stem cell-based therapy development service for autoimmune disease treatment.
Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, are multipotent stromal cells with the abilities of self-renewal and multi-directional differentiation. MSCs were originally found in the stromal compartment of bone marrow in the 1960s, but later were identified as important components of other adult organ tissue stroma, including muscle, peripheral blood, umbilical cord tissue, skeletal muscle, teeth, etc. The multi-differentiation capabilities led to an early emphasis on the development and utilization of their regeneration potential, however, new properties of these MSCs were gradually found since 2002. And it has been found that MSCs also express a variety of surface markers (such as CD73, CD90, and CD105), produce multiple immunomodulatory molecules (such as indoleamine 2,3-dioxygenase, interleukins, transforming growth factor, and prostaglandin E2), as well as secret adhesion molecules.
Over the past several decades, MSCs have been widely studied in cell-based therapies owing to their excellent characteristics of multilineage differentiation potential, anti-inflammation, immunosuppression, immunomodulation, affinity to injury or tumor site, regeneration, and easy to culture and preserve. MSCs-based cell therapy has been preclinically and clinically demonstrated to repair tissue damage in various disease conditions. Numbers of MSCs-based clinical trials have been registered and evaluated for the treatment of human diseases, including tumors, neurological disorders, autoimmune diseases, etc., exhibiting great applicational and therapeutic prospects.
Fig.1 Advantages of MSCs for clinical use. (Hmadcha, 2020)
Autoimmune diseases are a category of human chronic diseases caused by immunologic imbalance and loss of tolerance, which lead the immune system to attack self-components causing tissue damage. The conventional treatment of autoimmune diseases mainly relies on anti-inflammatory drugs and immunosuppressants, which have long-term side effects and increased susceptibilities. Therefore, MSCs-based cell therapy as an alternative has been developed for autoimmune disease treatment.
The anti-inflammation and immune modulation functions make MSC-based therapy attractive potential approaches SLE, a high mortality autoimmune disease affecting multiple organs. Research has pointed out that the proliferation and immunoregulation of bone marrow-derived MSCs isolated from SLE patients are impaired, and MSC deficiency or abnormality contributes to the pathogenesis of SLE. MSCs transplantation effectively and significantly inhibited the inflammation, decreased the levels of autoantibodies, and improved renal functions both preclinically and clinically.
Scleroderma, also known as systemic sclerosis, is a rare autoimmune disease characterized by fibrosis in the skin and internal organs, accompanied by small artery injury. MSC-based therapy has been explored to treat scleroderma due to the differentiation potential into endothelial cells in vitro and association with the issue angiogenesis of MSCs. The MSC-based therapy has been evaluated in different preclinical models, including bleomycin-induced pulmonary fibrosis, hypochlorous acid-induced scleroderma, and tight skin scleroderma mouse, as well as human scleroderma.
Crohn's disease is an inflammatory bowel disease involving multiple segments of the gastrointestinal tract. The first phase I clinical trial using autologous adipose-derived MSCs to treat Crohn's disease was reported in 2005, which showed a favorable therapeutic effect and no adverse effects. And the safety and efficacy of MSCs-based therapy for the treatment of Crohn's disease has been performed by many human trials using autologous and allogeneic MSC transplantation.
Fig.2 Different effects induced by systemic administration of mesenchymal stem. (Figueroa, 2012)
Currently, both autologous and allogenic-based cell therapy exhibits great application prospect and therapeutic value in terms of novel autoimmune disease therapy development. Added by our state-of-the-art technology platforms and years of experience, Creative Biolabs now offers one-stop tailored MSC-based therapy development services for the treatment of autoimmune diseases. Our services are characterized by:
Please directly contact us for more details. Our scientists are confident in offering satisfying supports and services.
For Research Use Only | Not For Clinical Use
Creative Biolabs is a world-leading CRO that is skilled in developing novel therapies,
especially in antibody and cell therapy for autoimmune diseases.
Copyright © 2023 Creative Biolabs. All Rights Reserved.